Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002679 · ClinicalTrials.gov registry record · Phase 2
Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
- 1
- Study location
NCT00002679 is a Phase 2 study of Breast Cancer that has completed, run by Yale University. The registered enrollment target is 89 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00002679, a Phase 2 study of Breast Cancer, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose sequential chemotherapy as adjuvant therapy in treating patients with stage II or stage III breast cancer who have four or more positive axillary lymph nodes.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG paclitaxel
- BIOLOGICAL filgrastim
- DRUG doxorubicin hydrochloride
- DRUG tamoxifen citrate
Study Locations (1)
Connecticut
- Yale Comprehensive Cancer Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 1994-02 |
| Est. Completion | 2002-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002679
The ClinicalTrials.gov registry entry for NCT00002679 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002679 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT00002679 about?
NCT00002679 is a clinical study titled "Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose sequential chemotherapy as adjuvant therapy in treating pat...
What is the current status of trial NCT00002679?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 1994-02. Estimated completion is 2002-01.
What conditions does trial NCT00002679 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00002679?
The interventions under investigation include: cyclophosphamide (DRUG), paclitaxel (DRUG), filgrastim (BIOLOGICAL), doxorubicin hydrochloride (DRUG), tamoxifen citrate (DRUG).
Who is sponsoring clinical trial NCT00002679?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002679 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.